Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Novo Nordisk invests $500 million in Ireland for oral Wegovy production
- Novo Nordisk began a major plant expansion in Ireland to support oral GLP‑1 supply, per Fierce Pharma.
- The investment signals scaling in obesity therapeutics manufacturing and shows a focus on manufacturing the product for markets outside of the U.S.
UK clinical trial reforms for 2026 highlight shift toward patient‑centered oversight
- Linical reports that the UK’s new clinical‑trial framework—part of a broader initiative to strengthen its life sciences competitiveness—emphasizes a more proportionate, patient‑centered regulatory model.
- The reforms aim to make the UK a more attractive environment for clinical research and innovation, supporting long‑term sector growth.
FDA decision-making draws scrutiny
- BioSpace reports that some regulatory experts warn that the U.S. Food and Drug Administration’s decision‑making appears to be increasingly viewed as top-down or “fiat‑like,” with diminishing consensus processes.
- According to the article, in 2025 the FDA not only had fewer advisory committee panels but also went against the recommendations of the panels 43% of the time.
Weight-loss drugs show promise in preventing heart attack complications
- Per The Guardian, a UK study found that GLP-1 weight-loss drugs could help prevent “no-reflow,” a dangerous post-heart attack complication affecting up to half of all patients, by relaxing constricted blood vessels in the heart.
- Published in Nature Communications, the research suggests these widely used drugs could be repurposed as a potentially life-saving treatment for heart attack recovery, beyond their established roles in obesity and diabetes.
FDA clarifies when follow‑on drugs can earn three‑year exclusivity
- A new draft guidance explains that drugs relying on previously approved products may still qualify for three years of clinical investigation exclusivity if they include new, non‑duplicative clinical trials, distinct from the five‑year new chemical entities or seven‑year orphan exclusivities.
- According to Endpoints News, the FDA aims to incentivize development of new indications, dosage forms, strengths, dosing regimens, and patient populations, while excluding routine pharmacokinetics and bioavailability studies, placebo‑only trials, or standard safety monitoring, and laying out criteria for when new trial cohorts or arms can count as qualifying clinical investigations.
For more insights in life sciences, check out RSM’s industry outlook.
